________________________________________________________
The information you provide to us for this Free Case Evaluation will be treated as strictly confidential. You will get a reply from us no later than the next business day. Submitting a case evaluation does not obligate you to hire our law firm for your lawsuit. We handle all cases on a contingency fee basis, which means that you will make no payment for our legal services until after we have succeeded in getting legal compensation for you.
NOTE: This Case Evaluation form can also be completed for situations that involve other incretin mimetic drugs which are used as diabetes medications, such as Bydureon, Januvia, and Victoza -- even in there is no Byetta involved.
______________________________________________________________________________
Diabetes drugs in the incretin mimetic class -- and their manufacturers -- include:
Exenatide (Byetta, Bydureon / injection) -- Amylin, which was acquired by Bristol Myers Squibb (BMS), which co-markets with Astra-Zeneca (AZ);
Liraglutide (Victoza / injection) -- Novo Nordisk;
Sitagliptin (Januvia, Janumet, Janumet XR, Juvisync / tablets) -- Merck;
Saxagliptin (Onglyza, Kombiglyze XR / tablets) -- BMS/AZ;
Alogliptin (Nesina, Kazano, Oseni / tablets) -- Takeda; and,
Linagliptin (Tradjenta, Jentadueto / tablets) -- Boehringer Ingelheim
________________________________________________________
My Articles About Byetta
Side Effects Blog
FDA Letters To AstraZeneca And Novo Nordisk Approve Addition Of Information About Increased Risk For Medullary Thyroid Carcinoma (MTC)
SUMMARY: Each of these March 2015 FDA letters, to AstraZeneca and to Novo Nordisk respectively, contain this paragraph:
We also refer to our letter dated October 7, 2014, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for long-acting GLP-1 receptor agonist products. This information pertains to the risk of medullary thyroid carcinoma.
In both AstraZeneca’s Bydureon Prescribing Information and Novo Nordisk’s Victoza Prescribing Information, the March 2015 label revisions concerning medullary thyroid carcinoma (MTC) can be seen in the so-called “Black Box” warning at the beginning of that document as well as at part 5.1 Risk of Thyroid C-cell Tumors in the Warnings and Precautions section.
As you may know, these diabetes drugs, Bydureon and Victoza, are alleged to have caused thyroid cancer and pancreatic cancer in drug injury lawsuits filed against the responsible pharmaceutical companies.
Earlier Byetta articles by Tom Lamb on the Drug Injury Watch blog: